Clinical trials on Asthma

Asthma: An Overview

Asthma is a chronic respiratory condition characterized by the inflammation and narrowing of the airways, leading to difficulty in breathing. It is a common ailment affecting individuals of all ages, though it often begins in childhood. The exact cause of asthma remains unclear, but it is known to be influenced by a combination of genetic and environmental factors. Symptoms can vary from mild to severe and include wheezing, coughing, chest tightness, and shortness of breath. These symptoms often worsen at night or during exercise, significantly impacting the quality of life of those affected.

Triggers and Management

Environmental factors play a significant role in triggering asthma symptoms. Common triggers include allergens (such as pollen, dust mites, and pet dander), air pollution, respiratory infections, physical activity, cold air, and stress. Identifying and avoiding these triggers are crucial steps in managing asthma effectively. Treatment typically involves the use of inhalers to deliver medication directly to the lungs, reducing inflammation and opening the airways. There are two main types of inhalers: quick-relief inhalers for immediate symptom management and long-term control inhalers used daily to prevent symptoms and attacks. In addition to medication, lifestyle changes, and regular monitoring, asthma action plans are tailored to each individual’s needs, helping them to control their condition and lead active lives.


While asthma cannot be cured, with proper management, individuals can control their symptoms and minimize the impact on their daily lives. It is essential for asthma sufferers to work closely with healthcare providers to develop a comprehensive management plan that includes medication, avoidance of triggers, and lifestyle adjustments. By doing so, most people with asthma can maintain normal or near-normal activity levels, enjoying a high quality of life despite the challenges posed by this chronic condition.

  • CT-EU-00057838

    Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    BelgiumCzechiaDenmarkFinlandFranceGermanyHungaryItalyPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Asthma treatment study for kids: comparing two medications

    This study is for children aged 6 to 11 with asthma. It compares the effectiveness and safety of two medications: QMF149 (a combination of indacaterol acetate and mometasone furoate) and budesonide. The study involves a cross-over design where children will receive both treatments for 12 weeks each, with a total duration of 37 weeks. It aims to find out which medication is better for controlling asthma symptoms in children. The study measures breathing function and asthma control. Safety and side effects are closely monitored. Participation could provide insights into better asthma management for kids.

  • Assessing new asthma treatment methods: a mepolizumab study

    This clinical trial investigates new methods of administering mepolizumab, a medication for severe asthma. It compares the effects of self-administered mepolizumab using an auto-injector pen against administration by a nurse with a pre-filled syringe. The study focuses on asthma control, treatment compliance, and patient satisfaction. It’s crucial for determining the effectiveness and practicality of self-administration in managing severe asthma, potentially enhancing patient independence and treatment outcomes.

  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    CzechiaFranceGermanyHungaryItalyPolandSpainUnited Kingdom
  • Investigating a new inhaler’s impact: comparative study in asthma treatment

    The study is designed to assess whether PT010, a new inhaler, can be beneficial for adults and teenagers with poorly managed asthma. PT010 comprises three active ingredients: budesonide, glycopyrronium, and formoterol. The comparative analysis aims to determine the effectiveness and safety of PT010 in comparison to another inhaler containing budesonide and formoterol, as well as the widely used Symbicort inhaler. The study will span from 24 to 52 weeks and involve approximately, 2200 participants from various locations. The primary focus will be on the improvement of lung function within 24 weeks, alongside evaluating the reduction in the frequency of asthma attacks and its impact on quality of life and respiratory control.

  • Study on tezepelumab’s impact on severe asthma in children

    This medical study is testing a new medication, called Tezepelumab, to see if it can help children between the ages of 5 to 12 years old who have severe asthma. The study will take place at multiple centers and will compare the results of kids receiving Tezepelumab with those receiving a placebo, which is a substance that doesn’t contain any medicine. To maintain fairness, the study will be double-blind, meaning both the doctors and patients won’t know who’s taking the real medicine and who’s taking the placebo. The study will take around a year, with an additional 3 months follow-up at the end. If eligible, all children have the chance to receive the active Tezepelumab medication after the study. This is to evaluate the benefits and safety of Tezepelumab as a treatment for severe asthma.

    FranceHungaryNetherlandsPolandSpainUnited Kingdom
  • Benralizumab’s impact on severe asthma study

    The study will examine the effects of a drug called benralizumab on people suffering from a severe type of asthma called eosinophilic asthma. Scientists will do this by using special imaging technology called functional airway imaging (FRI) to take pictures of the lungs before and after treatment. It’s an open-label trial, which means everyone knows that the asthma drug under investigation is benralizumab. The study will last from 15 to 23 weeks. Participants in this study must be adults (18 years of age or older), both men and women, who already have severe eosinophilic asthma. Their asthma is not currently well treated with regular inhalers or other asthma medications. One of the goals of the study is to see if benralizumab helps reduce airway resistance and clear mucus in the lungs. Scientists will measure parameters such as lung volume, airway resistance and mucus accumulation.

    BelgiumFrancePortugalSpainUnited Kingdom
  • Exploring new asthma treatment for adults

    This clinical trial evaluates londamocitinib (AZD4604), a potential new treatment for adults with moderate-to-severe asthma uncontrolled by standard inhalers (ICS-LABA). Participants will receive AZD4604 or a placebo via a dry-powder inhaler over 12 weeks. The trial aims to assess the drug’s effectiveness in managing asthma symptoms and its safety. It focuses on adults whose asthma is not well-controlled by current medications, seeking to offer a new therapeutic option.

    BulgariaDenmarkFranceGermanySpainSwedenUnited Kingdom
  • Asthma control study: comparing two inhalers over 12 weeks

    This study compares two inhalers for asthma control over 12 weeks. One combines budesonide and formoterol fumarate, and the other contains only budesonide. Around 340 adults and teens with poorly controlled asthma despite current treatment will participate. The study measures lung function, asthma symptoms, and medication safety. It’s a double-blind trial, meaning neither participants nor researchers know who receives which inhaler.

  • Advancing asthma management: study evaluates triple therapy inhaler

    This Phase 3 study evaluates the PT010 inhaler, a combination of budesonide, glycopyrronium, and formoterol, in adults and adolescents with inadequately controlled asthma. The study compares PT010 to standard treatments, assessing its effectiveness in improving lung function and reducing asthma exacerbations. Approximately, 2200 participants will be enrolled and monitored over 24 to 52 weeks. The trial aims to improve asthma management and quality of life for those with persistent symptoms despite current treatments.

    CzechiaGermanyGreecePortugalSlovakiaUnited Kingdom
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    BulgariaGermanyHungaryItalyNetherlandsPolandRomaniaSlovakiaSloveniaSpainUnited Kingdom
  • Asthma control study with budesonide and formoterol inhaler for adults and teens

    This is a 24-week medical study looking at the effectiveness and safety of a combined budesonide and formoterol fumarate inhaler. This inhaler is for grown-ups and teenagers who have asthma that isn’t under good management. The study wants to see if the combined inhaler works better than just using the budesonide inhaler or another available treatment. In this study, there will be three groups using different inhalers, but they won’t know which one they’re taking to ensure fairness. We measure effectiveness by seeing if their asthma symptoms get better and if they’re using less of their emergency relief inhaler. We will also be asking them questions about their quality of life with asthma.